A review of cost–effectiveness comparisons for overactive bladder treatments: which is the most cost-effective for improving quality of life?

References

• Haylen BT , de Ridder D , Freeman RM , et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29(1):4-20
   PubMed Web of Science ®Google Scholar
• Irwin DE , Milsom I , Hunskaar S , et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50(6):1306-14
   PubMed Web of Science ®Google Scholar
• Coyne KS , Sexton CC , Irwin DE , et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008;101(11):1388-95
   PubMed Web of Science ®Google Scholar
• Robinson D , Cardozo L . Overactive bladder: diagnosis and management. Maturitas 2012;71(2):188-93
   PubMed Web of Science ®Google Scholar
• Irwin DE , Mungapen L , Milsom I , et al. The economic impact of overactive bladder syndrome in six Western countries. BJU Int 2009;103(2):202-9
   PubMed Web of Science ®Google Scholar
• Sonnenberg FA , Beck JR . Markov models in medical decision making: a practical guide. Med Decis Making 1993;13(4):322-38
   PubMed Web of Science ®Google Scholar
• Jönsson B . Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004;22(Suppl 4):5-10
   PubMed Web of Science ®Google Scholar
• Sacco E , Tienforti D , D’Addessi A , et al. Social, economic, and health utility considerations in the treatment of overactive bladder. Open Access J Urol 2010;2:11-24
   PubMedGoogle Scholar
• Grosse SD . Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008;8(2):165-78
   PubMedGoogle Scholar
• Kobelt G , Jönsson L , Mattiasson A . Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn 1998;17(6):599-611
   PubMed Web of Science ®Google Scholar
• Johannesson M , O’Conor RM , Kobelt-Nguyen G , Mattiasson A . Willingness to pay for reduced incontinence symptoms. Br J Urol 1997;80(4):557-62
   PubMedGoogle Scholar
• Arikian SR , Casciano J , Doyle JJ , et al. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Manag Care Interface 2000;13(2):88-94
   PubMedGoogle Scholar
• O’Brien BJ , Goeree R , Bernard L , et al. Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. Clin Ther 2001;23(12):2038-49
   PubMed Web of Science ®Google Scholar
• Appell RA , Sand P , Dmochowski R , et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001;76(4):358-63
   PubMed Web of Science ®Google Scholar
• Getsios D , Caro JJ , Ishak KJ , et al. Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder. Clin Ther 2004;26(3):431-8
   PubMed Web of Science ®Google Scholar
• Hughes DA , Dubois D . Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics 2004;22(16):1047-59
   PubMed Web of Science ®Google Scholar
• Guest JF , Abegunde D , Ruiz FJ . Cost Effectiveness of Controlled-Release Oxybutynin Compared with Immediate-Release Oxybutynin and Tolterodine in the Treatment of Overactive Bladder in the UK, France and Austria. Clin Drug Investig 2004;24(6):305-21
   PubMed Web of Science ®Google Scholar
• Speakman M , Khullar V , Mundy A , et al. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin 2008;24(8):2173-9
   PubMed Web of Science ®Google Scholar
• Chapple CR , Martinez-Garcia R , Selvaggi L , et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48(3):464-70
   PubMed Web of Science ®Google Scholar
• Pradelli L , Iannazzo S . Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation. J Med Econ 2009;12(1):25-35
   PubMedGoogle Scholar
• Hakkaart L , Verboom P , Phillips R , Al MJ . The cost utility of solifenacin in the treatment of overactive bladder. Int Urol Nephrol 2009;41(2):293-8
   PubMed Web of Science ®Google Scholar
• Milsom I , Axelsen S , Kulseng-Hansen S , et al. Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Acta Obstet Gynecol Scand 2009;88(6):693-9
   PubMed Web of Science ®Google Scholar
• Chapple CR , Rechberger T , Al-Shukri S , et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93(3):303-10
   PubMed Web of Science ®Google Scholar
• Cardozo L , Lisec M , Millard R , et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172(5 Pt 1):1919-24
   PubMed Web of Science ®Google Scholar
• Cardozo L , Thorpe A , Warner J , Sidhu M . The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int 2010;106(4):506-14
   PubMed Web of Science ®Google Scholar
• Chapple CR , Khullar V , Gabriel Z , et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54(3):543-62
   PubMed Web of Science ®Google Scholar
• Herschorn S , Vicente C , Piwko C . Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder. J Med Econ 2010;13(3):508-15
   PubMedGoogle Scholar
• Herschorn S , Stothers L , Carlson K , et al. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol 2010;183(5):1892-8
   PubMed Web of Science ®Google Scholar
• Hart WM , Abrams P , Munro V , et al. Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom. J Med Econ 2013;16(10):1246-54
   PubMedGoogle Scholar
• Arlandis-Guzman S , Errando-Smet C , Trocio J , et al. Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model. BMC Urol 2011;11:9
   PubMed Web of Science ®Google Scholar
• Verheggen BG , Lee R , Lieuw On MM , et al. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder. J Med Econ 2012;15(3):586-600
   PubMedGoogle Scholar
• Kaplan SA , Roehrborn CG , Rovner ES , et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296(19):2319-28
   PubMed Web of Science ®Google Scholar
• Coyne KS , Sexton CC , Thompson CL , et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009;104(3):352-60
   PubMed Web of Science ®Google Scholar
• Kalsi V , Popat RB , Apostolidis A , et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 2006;49(3):519-27
   PubMed Web of Science ®Google Scholar
• Wu JM , Siddiqui NY , Amundsen CL , et al. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. J Urol 2009;181(5):2181-6
   PubMed Web of Science ®Google Scholar
• Cruz F , Herschorn S , Aliotta P , et al. Efficacy and safety of onabotulinum toxin A in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011;60(4):742-50
   PubMed Web of Science ®Google Scholar
• Ginsberg D , Gousse A , Keppenne V , et al. Phase 3 efficacy and tolerability study of onabotulinum toxin A for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012;187(6):2131-9
   PubMed Web of Science ®Google Scholar
• Carlson JJ , Hansen RN , Dmochowski RR , et al. Estimating the cost-effectiveness of onabotulinum toxin A for neurogenic detrusor overactivity in the United States. Clin Ther 2013;35(4):414-24
   PubMed Web of Science ®Google Scholar
• Leong RK , de Wachter SG , Joore MA , van Kerrebroeck PE . Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int 2011;108(4):558-64
   PubMed Web of Science ®Google Scholar
• Siddiqui NY , Amundsen CL , Visco AG , et al. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol 2009;182(6):2799-804
   PubMed Web of Science ®Google Scholar
• Getsios D , El-Hadi W , Caro I , Caro JJ . Pharmacological management of overactive bladder: a systematic and critical review of published economic evaluations. Pharmacoeconomics 2005;23(10):995-1000
   PubMed Web of Science ®Google Scholar